Phil Johnson

Company: Interius BioTherapeutics

Job title: Chief Executive Officer

Seminars:

In Vivo Engineering of CAR-T & CAR-NK for Autoimmune Disease 11:30 am

Engineering T and NK cells directly in vivo to create antigen-specific CAR cells Bypassing and eliminating all aspects of ex vivo cell manufacturing Creating “faster, better, cheaper” autologous CAR cells without the need for chemotherapyRead more

day: Conference Day One